1 Min Read
Aug 29 (Reuters) - Resverlogix Corp
* under CANTOS trial treatment with Resverlogix’ apabetalone has demonstrated a reduction in inflammatory mediator il-6 by 29 percent Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.